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Abstract
Background: The insulin receptor (IR) exists in two isoforms, A and B, and the isoform expression pattern is tissue-specific.
The C-terminus of the insulin B chain is important for receptor binding and has been shown to contact the IR just adjacent
to the region where the A and B isoforms differ. The aim of this study was to investigate the importance of the C-terminus of
the B chain in IR isoform binding in order to explore the possibility of engineering tissue-specific/liver-specific insulin
analogues.
Methodology/Principal Findings: Insulin analogue libraries were constructed by total amino acid scanning mutagenesis.
The relative binding affinities for the A and B isoform of the IR were determined by competition assays using scintillation
proximity assay technology. Structural information was obtained by X-ray crystallography. Introduction of B25A or B25N
mutations resulted in analogues with a 2-fold preference for the B compared to the A isoform, whereas the opposite was
observed with a B25Y substitution. An acidic amino acid residue at position B27 caused an additional 2-fold selective
increase in affinity for the receptor B isoform for analogues bearing a B25N mutation. Furthermore, the combination of
B25H with either B27D or B27E also resulted in B isoform-preferential analogues (2-fold preference) even though the
corresponding single mutation analogues displayed no differences in relative isoform binding affinity.
Conclusions/Significance: We have discovered a new class of IR isoform-selective insulin analogues with 2–4-fold
differences in relative binding affinities for either the A or the B isoform of the IR compared to human insulin. Our results
demonstrate that a mutation at position B25 alone or in combination with a mutation at position B27 in the insulin
molecule confers IR isoform selectivity. Isoform-preferential analogues may provide new opportunities for developing
insulin analogues with improved clinical benefits.
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Introduction
Insulin is a small globular protein composed of two polypeptide
chains, A (21 residues) and B chain (30 residues), which are
covalently linked by two interchain disulfide bridges [1]. The
biological effects of insulin are mediated through the insulin
receptor (IR), a covalent dimer consisting of two extracellular
insulin-binding a-subunits and two transmembrane b-subunits
disulfide-bonded in a b-a-a-b conformation (reviewed in [2]). Due
to alternative splicing of exon 11 of the IR gene, the IR exists as
two isoforms, isoform A (IR-A) and isoform B (IR-B), which differ
in the absence or presence of a 12 amino acid sequence,
respectively, located at the C-terminal end of the a-subunit [3].
The isoform expression pattern is regulated in a highly tissue-
specific manner, which is more or less conserved amongst species
[3–6]. In humans, both isoforms are present in tissues such as
skeletal muscle, adipose tissue, kidney, placenta, and heart;
however, IR-B is the most abundant IR isoform found in the
insulin-responsive tissues. The IR-B is predominantly expressed in
the liver (.90–95% IR-B) and this expression pattern appears
highly conserved among species, while IR-A is the dominant
isoform found in the brain, spleen, fetal tissues, as well as in several
cancers [3–10]. The abundance of the two isoforms has further
been suggested to be dependent on cell differentiation and
developmental stage [6,7]. The two insulin receptor isoforms have
also been reported to display functional differences such as slight
differences in insulin affinity, internalization kinetics as well as
signalling capacity and dynamics [11–15], but one of the most
distinct being the difference in IGF-I and IGF-II affinity [7,16].
Compared to insulin binding, both IR isoforms display low IGF-I
binding affinities, however, IR-A has a higher affinity for both
IGFs than IR-B and is in fact able to bind IGF-II with an affinity
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the exact physiological significance of the above-mentioned
observations remains unclear and research regarding the func-
tional differences between the two IR isoforms is therefore still
ongoing. Decades of investigations on insulin-receptor interactions
have generated numerous insulin analogues with different IR
binding properties. However, in this paper, we describe for the
first time the engineering of receptor isoform-selective insulin
analogues.
The present study was initially motivated by the multifaceted
role of the C-terminal end of the B chain. This segment of the
insulin molecule plays a fundamental role in dimer formation
[1,17], which is important for insulin storage in the b-cell. In
addition, the B chain C-terminus is of great importance for
receptor binding [18–21]. Residues B23–B26 are considered part
of insulin’s ‘classical’ binding surface [18] and are also essential for
the negative cooperativity observed in binding [22]. Photo-affinity
cross-linking studies have in fact established a direct contact
between B24–B27 derivatives and distinct sites on the IR [21,23–
25]. Another interesting finding is that deletion of residues B26–
B30 does not affect the in vitro binding potency of insulin given that
PheB25 is amidated [26]; however, studies of modifications in the
C-terminus of the B chain have provided insulin analogues with
interesting binding properties [19,20,27]. Furthermore, it is a
commonly held view that the B chain C-terminus detaches from
the hydrophobic core and rearranges to expose a buried functional
surface comprising PheB24 and part of the N-terminal A chain
upon receptor binding [28–31], although the extent of the
conformational change remains unknown. Interestingly, position
B24 and B25 are also sites of diabetes-associated mutations
(B24Ser – insulin Los Angeles; B25Leu – insulin Chicago) [32], which
underline the importance of the aromatic region in receptor
binding.
We therefore decided to perform a comprehensive structure-
function analysis on certain positions in the C-terminal part of the
insulin B chain by total amino acid scanning mutagenesis, a
powerful method recently developed [33] by which the resulting
single-substitution insulin analogues are individually evaluated in
terms of relative IR-A and IR-B binding potencies compared to
human insulin. The initial library screening and the following
engineering of library combinations resulted in the discovery of
analogues with 2–4-fold differences in relative binding affinities for
the two receptor isoforms.
Materials and Methods
Miscellaneous
Human insulin (HI), [
125I]TyrA14-labelled insulin and immo-
bilized Achromobacter lyticus protease (ALP) were from Novo Nordisk
A/S. Binding assays were performed using IR-specific monoclonal
mouse antibody 83-7 [34] licensed from Dr. K. Siddle (University
of Cambridge, Cambridge, U.K.) and solubilized human insulin
receptor (holoreceptor) semipurified by wheat germ agglutinin
chromatography from BHK cells, which were stably transfected
with the pZem vector containing either the human IR-A or IR-B
insert [35]. Materials, strains, general molecular biology tech-
niques, purification of analogues and receptors, and yeast
expression system were as previously published ([33] and
references therein) unless otherwise mentioned.
Analogue construction and expression in yeast
Vector construction, precursor expression and conversion, and
quantification of the insulin analogues were performed as recently
published [33]. Briefly, insulin precursor DNA constructs were
transformed into Saccharomyces cerevisiae strain MT663. The insulin
precursors were expressed as proinsulin-like fusion proteins (5 mL
cultures), with an N-terminal removable spacer peptide and mini
C-peptide. The single-chain precursors were enzymatically
converted into mature two-chain desB30 (insulin lacking the
amino acid at position B30) insulin analogues using lysine specific
ALP. Analogue concentrations were determined by reverse-phase
high-performance liquid chromatography using human insulin as
an external standard. All amino acid substitutions and full
conversion of the precursors were confirmed by matrix-assisted
laser desorption ionization time-of-flight mass spectrometry.
Insulin receptor binding assay
IR binding of the insulin analogues were determined by
competition of [
125I]TyrA14-labelled insulin binding in a scintil-
lation proximity assay (SPA) (analogues containing Cys and Lys
substitutions were excluded from the SPA due to potential
disulfide misparring or probable ALP cleavage in the conversion
step, respectively) as recently published [33] and data from the
SPA were analyzed according to the four-parameter logistic model
[36] assuming a common slope, basal and maximal response level
of the curves for human insulin and the insulin analogues. The
percentage of tracer bound in the absence of competing ligand was
less than 15% in all assays, to prevent ligand-depletion artifacts
and ,14-fold changes in responses were obtained. The affinities
(picomolar affinity range) of the analogues are calculated relative
to that of human insulin [IC50(insulin)/IC50(analogue)6100%] mea-
sured within the same plate.
Crystal structure determination
Crystals were obtained by the sitting drop vapor diffusion
method from a reservoir solution containing 0.8 M K/NaTar-
trate, 0.1 M Tris pH 8.5, 0.5% PEG MME 5000 and belong to
the cubic space group (I213). Data were collected with a rotating
anode (Rigaku, MicroMax-007HF) equipped with a MarCCD
detector and processed by XDS [37]. The structure was solved by
molecular replacement using Molrep [38] with an in house
structure as search model. Data refinement and model building
was made using the programs Refmac [39] and Coot [40]. Further
details about data collection and refinement statistics are available
as Supporting Information (Table S1) on the PLoS ONE web site.
Results and Discussion
Insulin analogues with 2-fold differences in relative IR isoform
affinity were discovered by amino acid scanning mutagenesis of
the aromatic locus PheB24-PheB25-TyrB26 and the two neigh-
bouring positions in the C-terminus of the B chain. Subsequently,
the concept of differential IR isoform binding was further
examined by engineering several analogues with multiple
mutations of which some were identified as having 2–4-fold
differences in relative IR isoform affinity. Both IR-A and IR-B-
selective analogues were engineered in the present study and
position B25 was identified as the common denominator involved
in receptor isoform selectivity.
The insulin precursors were individually expressed in S. cerevisiae
and the analogue precursor expression yields of the corresponding
insulin analogues (analogues listed in Table 1), all exceeded that of
wild-type precursor, indicating correct processing and folding in
the yeast cell [41]. Following enzymatic conversion of the
precursors into mature two-chain insulin analogues, the relative
receptor binding affinities of the analogues were determined using
either IR-A or IR-B (wild-type holoreceptor) purified from BHK
cells (see [33] for a more detailed description of the scintillation
IR Isoform-Selective Analogues
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confirmed by a membrane-bound receptor assay for a selection of
the analogues (data not shown). The validity of using insulin
analogues taken directly from yeast supernatant in the IR binding
experiments has previously been clearly established [33]. Exam-
ples of competition binding curves are given in Figure 1.
It has been reported that human insulin exhibits a ,2-fold
higher absolute affinity for IR-A than for IR-B, though both
receptor isoforms bind insulin with high affinity [5,11] and it is
therefore important to note that in the present study the relative
binding affinities of the analogues were compared to human
insulin and solely by comparing the human insulin standard and
insulin analogue tested within the same plate. When performing
binding assays on both IR-A and IR-B a very high correlation
between the relative affinities determined for the two receptor
isoforms is normally observed (see ref [33], which includes .100
insulin analogues). We routinely perform IR assays on vast
numbers of insulin analogues including the commercially available
insulin analogues and X10 (also known as AspB10) on both
isoforms of the receptor. We do not find that any of these
analogues display isoform selectivity (manuscript in preparation),
including insulin detemir and insulin aspart. It has recently been
reported that insulin X10 displays a 3-fold higher relative affinity
for IR-A than IR-B compared to human insulin [42]; however this
is in contrast to our findings (manuscript in preparation) and to
Sciacca et al. [43]. Furthermore, we have tested the desB30
version of X10 [B10D, desB30] as well as [B10E, desB30] and
determined that these analogues bind with the same relative
affinity to both isoforms of the IR [33], which is in accordance
with our X10 data.
In this study, single-mutation libraries were constructed and
evaluated in terms of receptor binding potency for both isoforms of
the IR. Interestingly, anomalies between the relative IR-A and IR-
B binding affinities were found in the [B25X] library, in which X
represents any of the 20 naturally occurring amino acids. The
systematic amino acid scanning mutagenesis revealed that
analogues [B25A] and [B25N] had increased preferences for IR-
B compared to IR-A with respect to binding, while the opposite
was observed for the [B25Y] analogue (see Table 1). As expected,
the vast majority of the amino acid substitutions at position B25
disrupted receptor binding, being markedly decreased for both the
[B25A] and [B25N] analogues, whereas an increase in affinity was
observed for the [B25Y] analogue. The IR-B preferential [B25N]
analogue, which displayed a 2-fold higher relative binding affinity
for IR-B (860.7%) compared to IR-A (460.2%), was further
investigated. Due to the location of a Thr residue at B27, the
replacement of PheB25 with Asn creates a potential glycosylation
site and analysis by RP-HPLC and LC-MS showed that
approximately 35% of the secreted B25N precursor was
glycosylated. In the above mentioned binding affinities for the
[B25N] analogue, the glycosylated [B25N] analogue is assumed
not to participate in IR binding.
Figure 1. Representative IR competition binding curves. Displacement of
125I-labelled insulin by human insulin and insulin analogues from the
(A) A-isoform or the (B) B-isoform of the IR. The amount of bound
125I-labelled insulin as a percentage of bound
125I-labelled insulin in the absence of
unlabelled analogue is plotted against the concentration of unlabelled analogue. Data points are means 6 SEM of four measurements within one
assay (n=1). The
125I-labelled insulin was displaced with purified human insulin standard (*) or insulin analogues [A8H, B25H, B27E] (m), [A8H, B25N,
B27E] (.), and [A8H, B25N] (N).
doi:10.1371/journal.pone.0020288.g001









None 98641 0 0 651
A8H 308 308 1
B25A 360.3 660.8 2
B25H 33 32 1
B25Y 285678 157627 0.6
B27D 74 73 1
B27E 83 93 1
B25N 460.2 860.7 2
A8H, B25N 22644 4 652
B25H, B27E 13613 0 652
A8H, B25A, B27E 10612 4 622
A8H, B25Y, B27E 714631 459651 0.6
A8H, B25N, B27D 10613 8 644
A8H, B25N, B27E 15635 7 634
A8H, B25H, B27D 43648 2 672
A8H, B25H, B27E 67631 4 0 652
For analogues tested in at least three independent experiments, the mean
6 SD is presented. Analogues with no fold difference between IR-A and IR-B
binding affinity were tested once as part of the analogue library screening.
doi:10.1371/journal.pone.0020288.t001
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isoform binding for this analogue, an A8H mutation was
combined with the B25N mutation in order to increase the IR
binding affinity of the analogue and thereby also the robustness of
the assay. The A8H mutation has been demonstrated to cause an
approximately 3-fold increase in both IR binding and biological
activity compared to human insulin [44] and the binding data
from the [A8H] analogue in this study confirms the 3-fold increase
in binding affinity for both isoforms of the IR (see Table 1). For the
majority of protein-protein interactions, near simple additivity
applies for the free energy changes derived from multiple
mutations [45]. This is also generally observed for human insulin
where the additivity of the mutational effects often is employed
when designing analogues. However, exceptions can occur if the
mutated residues interact with each other or produce large
structural perturbations. Here, the A8H mutation is not in close
proximity to the aromatic patch at the C-terminal end of the
B chain and the mutation is therefore not believed to cause any
long-range structural perturbations, which can affect the diver-
gence in receptor isoform affinity [46].
Approximately 20% of the resulting [A8H, B25N] analogues
were found to be glycosylated, but more importantly the 2-fold
difference in relative IR isoform binding affinity was preserved.
The analogue displayed relative binding potencies of 2265% and
4465% for IR-A and for IR-B, respectively, compared to human
insulin, when the glycosylated analogue was assumed not to
participate in IR binding. To ensure that glycosylation had no
impact on the observed divergence in relative IR isoform affinity,
the yeast strain expressing [A8H, B25N] was fermented and the
secreted precursor enzymatically cleaved and purified (98%
purity). The purified and unglycosylated [A8H, B25N] analogue
retained its 2-fold difference in relative IR binding potency
demonstrating that glycosylation had no influence on the
difference in relative IR isoform binding.
Whereas PheB24 and TyrB26 pack against the core of the
molecule [1], the side chain at position B25 projects from the
surface of insulin and is able to form contacts with the amino acid
side chain at position B27, which also protrudes outwards from the
molecule. The [A8H, B25N, B27X] library was therefore
constructed in order to examine whether amino acid substitutions
of ThrB27 would affect the divergence in relative IR isoform
affinity observed for the [A8H, B25N] analogue. Interestingly, the
analogues from the [A8H, B25N, B27X] library all displayed $2-
fold differences (IR-B.IR-A) in relative binding affinities for the
two receptor isoforms. In fact, analogues [A8H, B25N, B27D] and
[A8H, B25N, B27E] both exhibited a 4-fold higher relative
binding affinities for IR-B than IR-A (see Table 1). However, the
single mutation analogues [B27D] and [B27E] showed no
considerable difference in relative receptor isoform binding
suggesting that in this analogue library, B25N is the determinant
of IR-B selectivity, while an acidic amino acid residue in position
B27 further enhances the difference in isoform binding.
To evaluate whether the remaining possible amino acid
substitutions at B25 including the IR-A preferential Tyr and IR-
B preferential Ala substitutions would be affected by an acidic
amino acid residue at position B27 with respect to IR isoform
binding, the [A8H, B25X, B27E] library was constructed and
receptor binding evaluated. The triple mutation library confirmed
the observed 2-fold differences in relative receptor isoform affinity
and the [A8H, B25A, B27E] analogue displayed relative binding
affinities of 1061% for IR-A and 2462% for IR-B, while the
[A8H, B25Y, B27E] analogue showed highly increased binding
affinities of 714631% and 459651% for IR-A and IR-B,
respectively, compared to human insulin. Surprisingly, the
[A8H, B25H, B27E] analogue was found to exhibit IR-B
selectivity (6763% on IR-A and 14065% on IR-B). The result
was considered puzzling given that either the [B25H] or [B27E]
analogue showed no considerable difference in relative IR isoform
binding affinity. To substantiate these results, the [B25H, B27E]
and [A8H, B25H, B27D] analogues were constructed and
receptor binding evaluated (see Table 1). Both analogues showed
2-fold higher relative IR-B binding compared to IR-A and
confirmed that a His mutation at position B25 in combination
with an acidic amino acid at position B27 results in IR-B selectivity
of the analogue.
When searching for an isoform selective insulin analogue, it
seemed plausible that a mutation in the C-terminus of the B chain
would be essential for isoform selectivity given that B25 and B27
have been shown to cross-link to a region at the C-terminus of the
IR a-chain, a segment knownas the CTpeptide, just adjacent to the
12-amino acid segment encoded by exon 11 [21,23,24]. The CT
peptide has been suggested to be directly involved in insulin binding
[21,47–49] and alanine mutations in this region have also been
shown to have differential effects on the ligand affinity of the two
receptor isoforms [50]. The fact that certain IR alanine mutations
are isoform-specific as shown by Whittaker et al. [50] indicates that
the structures of the IR-A and IR-B binding epitopes differ and our
findings corroborate this concept. This is also supported by the
difference in IR isoform affinity observed for IGF-I and IGF-II
[7,16]. Insulin and the IGFs have overlapping receptor binding sites
[51]; however, IGF-II is able to bind to IR-A, but not to IR-B with
an affinity similar to that of insulin [7,16].
While it is clear that position B25 is a key determinant for
isoform selectivity, the structure-activity relationships are less
obvious. A comparison of the relative binding affinities of the
isoform-specific analogues reveals that simple additivity of the
mutational effects does not apply for the analogues with mutations
both at position B25 and B27. This indicates an interaction
between the substituted residues. Analogue [B25N] displays the
same fold increase for both receptor isoforms when combined with
the A8H mutation, whereas the addition of B27E or B27D to the
A8H and B25N substitution causes a disproportionate change in
relative IR isoform affinities of the resulting analogues. The
addition of B27E or B27D would be expected to result in a
decrease in receptor affinity of the triple mutated analogues
assuming no intramolecular interactions occur and simple
additivity of the free energy change of the single mutations
applies. However, the expected decreases in relative binding
affinities were only evident for the A isoform, whereas increases in
relative binding affinities were observed for the B isoform of the
receptor (see Table 1).
To gain a further understanding of the structure-activity
relationships for the B isoform-specific mutations, crystal structures
of analogues [A8H, B25N], [A8H, B25N, B27E] and [A8H,
B25H, B27E] were obtained by X-ray crystallography. As
expected, the A8H mutation did not cause any long-range
structural perturbations that affected the C-terminus of the
B chain, but under the conditions for crystal growth, no
intramolecular interactions between the B25 and B27 side chains
could be observed (see Figure 2B). However, the potential effect of
crystal packing forces has to be taken into account, when
investigating the intramolecular interactions between residues
located in the C-terminal end of the B-chain, which is part of the
insulin dimer interface. Dimer forming interactions could be
preferred prior to any possible B25–B27 interactions. Further-
more, the pH of the crystallisation buffer was 8.5. At this pH the
side chain of B25H is most likely unprotonated. The binding
assays were performed at near physiological pH, where B25H is
IR Isoform-Selective Analogues
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unprotonated B27E. A modelled structure was prepared, where
the side chain rotamer of B27E was varied to see whether the
distance between B25H and B27E would permit an interaction.
Figure 2C shows that the distance between the two residues is
2.6 A ˚, which suggests that a hydrogen bond interaction would be
possible. Complete clarification of the molecular details for
isoform-selectivity will most likely require a crystal structure of
both receptor isoforms in complex with insulin and/or the
isoform-specific analogues. Solution structures of the analogues
by NMR spectroscopy may also provide structural insight on
isoform selectivity.
In conclusion, total amino acid scanning mutagenesis of
positions B23–B27 of insulin and the further engineering of a
selection of multi-substituted analogues allowed for the construc-
tion of both IR-A and IR-B isoform-specific insulin analogues and
to identify position B25 as a key determinant for isoform
selectivity. The selectivity is reflected by a larger decrease in
affinity for one isoform than the other. Our results demonstrated
that a replacement of PheB25 with either Ala or Asn resulted in an
analogue with a 2-fold higher relative binding affinity for the B
isoform compared to the A isoform of the receptor, whereas the
opposite was observed when introducing a Tyr residue at this
position. Combining the A8H and B25N mutations with an acidic
amino acid residue at position B27 caused an additional 2-fold
selective increase in affinity for the B isoform of the receptor
resulting in analogues displaying 4-fold IR isoform preferences
with respect to binding. Surprisingly, the combination of B25H
with either B27E or B27D was also found to result in IR-B
preferential analogues (2-fold differences) despite the fact that the
corresponding single mutation analogues displayed no differences
in relative isoform binding affinity.
Endogenously produced insulin is secreted from the pancreas
directly into the portal vein and the liver is therefore exposed to
much higher concentrations of insulin than the periphery [52],
whereas subcutaneous administration of exogenous insulin leads to
a non-physiological insulin distribution, in which peripheral tissues
such as muscle and fat become relatively ‘over-insulinized’. Since
the tissue-specific isoform expression pattern is highly regulated
and IR-B is the vastly abundant isoform expressed in the liver
[3–5], an IR-B selective insulin analogue may demonstrate liver-
selectivity and consequently mimic the natural route of insulin
distribution. This could lead to improved blood glucose control
with a reduced risk of hypoglycaemia. In addition, a liver-selective
analogue may also lead to improved lipid profiles and a reduced
fat mass compared to the currently available insulin therapies.
To summarize, we have engineered several different insulin
receptor isoform-specific insulin analogues. Both IR-A and IR-B
selective analogues were constructed and these findings represent
the first description of receptor isoform-selective insulin analogues.
A more detailed characterization of the isoform-selective ana-
logues and their biological effects is requisite in order to fully
understand the underlying basis for this phenomenon and its
biological consequences (further in vivo and in vitro data are pending
submission). However, the insulin analogues presented in this
study may open new avenues for the engineering of a new class of
tissue-specific/liver-selective insulin analogues with improved
clinical benefits.
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